Social media

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/Q1...

The EU Joint Clinical Assessment (#JCA), launched in 2025, is reshaping how oncology and #ATMP trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing...

New analyses show that well-implemented DHTs can: - Reduce trial timelines by 3–5 months - Decrease enrollment requirements by up to 16% - Lower protocol amendment risk - Deliver meaningful ROI in both Phase II and Phase...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

Come along to Rüdiger Kaspera's Learning Lab at ASCPT, where he’ll dive into science and risk based strategies for designing oligonucleotide First‑in‑Human studies - covering toxicity, study design, PK/PD, population se...

Patient led organisations are shaping scientific and regulatory strategy in ultra rare diseases. Join our live panel as we bring together leaders whose work has contributed to gene therapies, accelerated approvals and ...

ADCs are transforming cancer treatment by combining targeted monoclonal antibodies with powerful cytotoxic agents. However their complexity poses bioanalytical challenges. Scientists face major challenges due to ADC he...

Understanding how clinical trials are delivered starts with clarity on the roles that shape them. Our latest blog explains how sponsors set the research agenda and retain oversight, how CROs manage operational delivery...

AI enabled SaMD is evolving quickly. But are we addressing model bias fast enough? Our latest blog explores how bias creeps into datasets and what developers must do to avoid perpetuating disparities in healthcare. - Im...

Regulatory change is coming to pediatric therapeutics. The EMA proposed a new MoA PIP requirement that could transform pediatric drug development and create an influx of more meaningful therapies. Learn from ICON exp...

ICON proudly supports International Childhood Cancer Day, reaffirming our commitment to advancing research and improving outcomes for children, survivors, and families affected by childhood cancer. In the past 5 years,...

As digital endpoints gain regulatory traction, sponsors who invest in endpoint strategy and validation today will be better positioned to run faster, more inclusive trials tomorrow. Digital health technologies are enabli...